183 related articles for article (PubMed ID: 16915367)
21. Pharmacokinetic interactions between omeprazole/pantoprazole and clarithromycin in health volunteers.
Calabresi L; Pazzucconi F; Ferrara S; Di Paolo A; Tacca MD; Sirtori C
Pharmacol Res; 2004 May; 49(5):493-9. PubMed ID: 14998561
[TBL] [Abstract][Full Text] [Related]
22. The role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazole.
Uno T; Sugimoto K; Sugawara K; Tateishi T
Ther Drug Monit; 2008 Jun; 30(3):276-81. PubMed ID: 18520598
[TBL] [Abstract][Full Text] [Related]
23. Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes.
Yasui-Furukori N; Takahata T; Nakagami T; Yoshiya G; Inoue Y; Kaneko S; Tateishi T
Br J Clin Pharmacol; 2004 Apr; 57(4):487-94. PubMed ID: 15025747
[TBL] [Abstract][Full Text] [Related]
24. St John's wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole.
Wang LS; Zhou G; Zhu B; Wu J; Wang JG; Abd El-Aty AM; Li T; Liu J; Yang TL; Wang D; Zhong XY; Zhou HH
Clin Pharmacol Ther; 2004 Mar; 75(3):191-7. PubMed ID: 15001970
[TBL] [Abstract][Full Text] [Related]
25. Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH.
Shirai N; Furuta T; Moriyama Y; Okochi H; Kobayashi K; Takashima M; Xiao F; Kosuge K; Nakagawa K; Hanai H; Chiba K; Ohashi K; Ishizaki T
Aliment Pharmacol Ther; 2001 Dec; 15(12):1929-37. PubMed ID: 11736724
[TBL] [Abstract][Full Text] [Related]
26. Plasma concentration of rabeprazole after 8-week administration in gastroesophageal reflux disease patients and intragastric pH elevation.
Yamano HO; Matsushita HO; Yanagiwara S
J Gastroenterol Hepatol; 2008 Apr; 23(4):534-40. PubMed ID: 17725594
[TBL] [Abstract][Full Text] [Related]
27. CYP2C19 polymorphism affects single-dose pharmacokinetics of oral pantoprazole in healthy volunteers.
Gawrońska-Szklarz B; Adamiak-Giera U; Wyska E; Kurzawski M; Gornik W; Kaldonska M; Drozdzik M
Eur J Clin Pharmacol; 2012 Sep; 68(9):1267-74. PubMed ID: 22418828
[TBL] [Abstract][Full Text] [Related]
28. Effect of CYP2C19 genotypes on the pharmacokinetic/pharmacodynamic relationship of rabeprazole after a single oral dose in healthy Chinese volunteers.
Sheng YC; Wang K; He YC; Yang J; Zheng QS
Eur J Clin Pharmacol; 2010 Nov; 66(11):1165-9. PubMed ID: 20838991
[TBL] [Abstract][Full Text] [Related]
29. Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir.
Mikus G; Schöwel V; Drzewinska M; Rengelshausen J; Ding R; Riedel KD; Burhenne J; Weiss J; Thomsen T; Haefeli WE
Clin Pharmacol Ther; 2006 Aug; 80(2):126-35. PubMed ID: 16890574
[TBL] [Abstract][Full Text] [Related]
30. Mass balance study of [14C] rabeprazole following oral administration in healthy subjects.
Setoyama T; Drijfhout WJ; van de Merbel NC; Humphries TJ; Hasegawa J
Int J Clin Pharmacol Ther; 2006 Nov; 44(11):557-65. PubMed ID: 17176622
[TBL] [Abstract][Full Text] [Related]
31. Effects of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans.
Furuta T; Ohashi K; Kobayashi K; Iida I; Yoshida H; Shirai N; Takashima M; Kosuge K; Hanai H; Chiba K; Ishizaki T; Kaneko E
Clin Pharmacol Ther; 1999 Sep; 66(3):265-74. PubMed ID: 10511062
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes.
Miura M; Tada H; Yasui-Furukori N; Uno T; Sugawara K; Tateishi T; Suzuki T
Eur J Clin Pharmacol; 2004 Nov; 60(9):623-8. PubMed ID: 15448955
[TBL] [Abstract][Full Text] [Related]
33. The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics.
Ishizawa Y; Yasui-Furukori N; Takahata T; Sasaki M; Tateishi T
Clin Pharmacokinet; 2005; 44(11):1179-89. PubMed ID: 16231968
[TBL] [Abstract][Full Text] [Related]
34. Enantioselective disposition of lansoprazole and rabeprazole in human plasma.
Miura M
Yakugaku Zasshi; 2006 Jun; 126(6):395-402. PubMed ID: 16755125
[TBL] [Abstract][Full Text] [Related]
35. Formation of omeprazole sulphone but not 5-hydroxyomeprazole is inhibited by grapefruit juice.
Tassaneeyakul W; Vannaprasaht S; Yamazoe Y
Br J Clin Pharmacol; 2000 Feb; 49(2):139-44. PubMed ID: 10671908
[TBL] [Abstract][Full Text] [Related]
36. Effect of fluvoxamine on the pharmacokinetics of roflumilast and roflumilast N-oxide.
von Richter O; Lahu G; Huennemeyer A; Herzog R; Zech K; Hermann R
Clin Pharmacokinet; 2007; 46(7):613-22. PubMed ID: 17596106
[TBL] [Abstract][Full Text] [Related]
37. Determination of rabeprazole enantiomers and their metabolites by high-performance liquid chromatography with solid-phase extraction.
Miura M; Tada H; Satoh S; Habuchi T; Suzuki T
J Pharm Biomed Anal; 2006 May; 41(2):565-70. PubMed ID: 16442771
[TBL] [Abstract][Full Text] [Related]
38. Effects of rabeprazole on the antiplatelet effects and pharmacokinetics of clopidogrel in healthy volunteers.
Funck-Brentano C; Szymezak J; Steichen O; Ducint D; Molimard M; Remones V; Azizi M; Gaussem P
Arch Cardiovasc Dis; 2013 Dec; 106(12):661-71. PubMed ID: 24246616
[TBL] [Abstract][Full Text] [Related]
39. Influence of lansoprazole and rabeprazole on mycophenolic acid pharmacokinetics one year after renal transplantation.
Miura M; Satoh S; Inoue K; Kagaya H; Saito M; Suzuki T; Habuchi T
Ther Drug Monit; 2008 Feb; 30(1):46-51. PubMed ID: 18223462
[TBL] [Abstract][Full Text] [Related]
40. Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status.
Sugimoto M; Furuta T; Shirai N; Kajimura M; Hishida A; Sakurai M; Ohashi K; Ishizaki T
Clin Pharmacol Ther; 2004 Oct; 76(4):290-301. PubMed ID: 15470328
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
